Viral Infectious Diseases Research Reagents

ProSci Incorporated is committed to supporting infectious diseases research. With the onset of the COVID-19 pandemic, the relevance of infectious disease research is heightened. For thousands of years, people were delivered helplessly to various kinds of infections, which often reached epidemic proportions and cost millions of lives. However, due to a lack of knowledge, the search for strategies to fight, heal, and prevent the spread of communicable diseases was unsuccessful for a long time.

It was not until the first microscopic observations of “little beasties” in the seventeenth century, the refutation of spontaneous generation, and the dissolution of the question, “What is the nature of infectious diseases?” that infectious disease could be understood, and progress is made toward eradication. We have benefitted from vaccination with diseases such as measles, mumps and chickenpox, and other childhood killers.

The discovery and production of penicillin started the modern era of successful treatment of bacterial infections. While new antibiotics need to be found, the fight against viral infections has not been as successful as that against bacteria.

Recent viral epidemics and pandemics have devastated lives and populations on a global scale. To support biomedical viral research and epidemiological studies into these devastating diseases, ProSci Incorporated offers over 1,100 research reagents for the study of many known viral disease agents including Coronaviruses (SARS, MERS, COVID-19) HIV, and Influenza.